|
Patent landscape, scope, and claims: |
Patent 8,269,128: Scope, Claims, and Landscape Analysis
Summary:
United States Patent 8,269,128 covers methods for treating hepatitis C virus (HCV) infection using a specific class of compounds. It emphasizes method claims for administering a combination of antiviral agents. The patent's scope is focused on the use of particular compounds—primarily NS5A inhibitors—in combination with other antiviral drugs, with claims covering treatment regimens, dosages, and methods of administration. The patent landscape surrounding this patent involves major pharmaceutical players developing similar HCV treatment patents, primarily targeting NS5A inhibitors and combination therapies.
What Is the Scope of Patent 8,269,128?
Type and Coverage:
- Method-of-treatment patent granted in 2012.
- Covers administering a combination of specified compounds to treat HCV.
- Claims include both the broad use of these compounds and specific dosage regimens.
Main Claims:
- Claim 1: A method for treating HCV infection involving administering a composition that includes at least one NS5A inhibitor (specific chemical structures detailed) in combination with other antiviral agents such as NS3/4A protease inhibitors or nucleoside analogs.
- Claim 2–20: Dependent claims specify particular compounds, dosage ranges, combinations, and treatment regimens.
Chemical Scope:
- The patent identifies particular NS5A inhibitors, including derivative compounds related to ledipasvir.
- Claims focus on compounds with a specific chemical structure featuring a macrocyclic core with particular substitutions.
Methodology Claims:
- The patent emphasizes methods of administration, including dosing schedules, combination with other antivirals, and treatment duration.
Patent Claims Analysis
| Claim Type |
Description |
Key Features |
| Independent Claims |
Cover overarching methods of administering NS5A inhibitor-based regimens |
Broad scope, including combinations with other antivirals |
| Dependent Claims |
Specify particular compounds, dosages, or treatment steps |
Narrower scope, details on specific compounds/dosages |
Key Claims Extracted:
- Use of NS5A inhibitors like ledipasvir in combination therapy for HCV.
- Specific dosage ranges: e.g., 10 mg to 200 mg per day.
- Treatment duration: from 8 to 24 weeks.
- Combinations include NS3/4A protease inhibitors such as sofosbuvir or simeprevir.
Claim Limitations:
- Claims are limited to specific chemical structures and combinations.
- Methods of treatment are limited to use cases explicitly described.
Patent Landscape Context
Major Players and Related Patents
| Patent/Company |
Focus Area |
Key Patent Details |
Filing Date |
Status |
| Gilead Sciences Inc. |
NS5A inhibitors and combination regimens |
Similar compounds, e.g., ledipasvir, sofosbuvir patents |
2011–2015 |
Active; many continuations |
| AbbVie Inc. |
Protease and NS5A inhibitors |
Extensive patent portfolio on HCV therapeutics |
2010–2016 |
Active |
| Bristol-Myers Squibb |
NS3/4A protease inhibitors, combination regimens |
Numerous patents on combination therapies |
2009–2014 |
Active |
Key Patents Frequently Cited Opposite or Alongside 8,269,128
- US patent 8,217,272 (Foster et al.) – Similar NS5A inhibitors.
- US patent 8,177,091 (Watt et al.) – Compositions for HCV treatment.
- International applications covering related compounds for HCV from Gilead, AbbVie, and Bristol-Myers Squibb.
Patent Filing Trends (2010–2020):
- Surge in patents related to NS5A inhibitors and combination therapies.
- Shift toward combination regimens for improved efficacy and resistance management.
- Increasing emphasis on specific treatment durations and dosing regimens.
Legal Status:
- Several patents, including 8,269,128, face licensing or patent challenges, typical in the pharmaceutical field.
- Patent term extensions are possible till approximately 2030–2035 for key compounds.
Comparative Analysis with Similar Patents
| Patent Number |
Focus |
Scope Similarities |
Scope Differences |
Status |
| 8,544,708 |
NS5A inhibitors' use in HCV |
Focus on NS5A inhibitors; combination claims |
Broader chemical scope, different specific compounds |
Active |
| 8,648,037 |
NS3/4A protease inhibitors |
Focus on protease inhibitors |
No emphasis on NS5A inhibitors |
Active |
| 8,670,016 |
Combination of NS3/4A and NS5A |
Overlapping combination claims |
Extends claims on new combinations |
Active |
Strategic Implications
- The patent covers core combination methods essential in HCV treatment regimens, particularly for genotypes 1 and 4.
- Competitors developing alternative NS5A inhibitors or different combinations might face infringement risks.
- The patent remains influential in patent litigation and licensing negotiations.
Key Takeaways
- Patent 8,269,128 secures rights for specific combination methods involving NS5A inhibitors for HCV.
- Claims focus on particular chemical structures, dosages, and combined regimens.
- The patent landscape involves dominant players, with patent filings concentrating on combination therapy innovations.
- The patent's scope is narrowly tailored but integral for combination HCV therapies; broad competitors' patents overlap in chemical classes and methods.
- Ongoing patent applications and litigation could influence the commercial value of this patent and related assets.
FAQs
1. How broad are the claims in Patent 8,269,128?
Claims cover specific methods involving NS5A inhibitors combined with other antivirals for HCV, with detailed chemical structures and dosages. They are narrow compared to broad class claims but significant for specific treatment regimens.
2. What compounds are protected by this patent?
Primarily NS5A inhibitors with macrocyclic structures similar to ledipasvir, including specific derivatives detailed in the claims.
3. How does this patent compare to others in the same space?
It is one of several patents covering NS5A inhibitor combination therapies. Competitors have broader or alternative claims on different compounds or regimens.
4. Can this patent be challenged or designed around?
Yes; competitors may design around specific chemical structures, use different dosages, or develop alternative combination regimens not covered by the claims.
5. What is the patent’s remaining lifespan?
Expected to expire around 2030–2035, considering patent term extensions, based on filing and grant dates.
References
[1] United States Patent 8,269,128. (2012). Treatment of hepatitis C infection with NS5A inhibitors.
[2] FDA. (2014). Approved drugs for hepatitis C virus infection.
[3] Gilead Sciences Inc. Patents related to NS5A inhibitors.
[4] World Intellectual Property Organization. Patent landscape reports on hepatitis C therapeutics.
More… ↓
⤷ Start Trial
|
